Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382579 | 0.91 | — | — | |
| SCHEMBL28431559 | 0.65 | TSHR (0.50) | TSHR | |
| SCHEMBL28837054 | 0.63 | TSHR (0.47) | TSHR | |
| SCHEMBL29253986 | 0.63 | TSHR (0.47) | TSHR | |
| SCHEMBL7265484 | 0.63 | TSHR (0.39) | TSHR | |
| SCHEMBL8773850 | 0.61 | CYP3A4 (0.32) | — | |
| SCHEMBL27399560 | 0.61 | HCAR2 (0.43) | TSHR | |
| SCHEMBL891486 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL30362247 | 0.59 | TSHR (0.41) | TSHR | |
| 1,3,5-Trichlorobenzene SCHEMBL429512 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027362-B1 | 2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES | ABBOTT LAB (US) | 2005-06-29 | — | — | EP | claimed |
| US-6727229-B2 | MACROLIDE ANTIBIOTICS PLAY A THERAPEUTICALLY IMPORTANT ROLE, PARTICULARLY WITH THE EMERGENCE OF NEW PATHOGENS | ENANTA PHARMACEUTICALS, INC. | 2004-04-27 | — | — | US | claimed |
| WO-2004016634-A1 | Novel 11,12-Substituted Lactone Ketolide Derivatives Having Antibacterial Activity | ENANTA PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | claimed |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | claimed |
| US-6124269-A | NOVEL ERYTHROMYCIN DERIVATIVE ANTIBIOTIC EFFECTIVE AGAINST GRAM-NEGATIVE BACTERIA AND HAVING LESS POTENTIAL FOR DEVELOPING BACTERIAL DRUG RESISTANCE | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | claimed |
| EP-1027362-A1 | 2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES | Abbott Laboratories (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021871-A1 | 2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-05-06 | — | — | WO | claimed |
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1506214-B1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARM INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-20090149398-A1 | 6,11-3c-bicyclic 8a-azalide derivatives | MERCK SHARP & DOHME CORP. | 2009-06-11 | — | — | US | disclosed |
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-1992012983-A1 | A METHOD OF FLUORINATING BY USING N-FLUOROPYRIDINIUM PYRIDINE HEPTAFLUORODIBORATE | ALLIED-SIGNAL INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0471755-A1 | N-FLUOROPYRIDINIUM PYRIDINE HEPTAFLUORODIBORATE. | ALLIED SIGNAL INC (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5086190-A | Heating and reacting androstadienes with the complexes in solvent | ALLIED-SIGNAL INC. (US) | 1992-02-04 | — | — | US | disclosed |
| US-4996320-A | Thyroid inhibitors | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-02-26 | — | — | US | disclosed |
| WO-1990013541-A1 | N-FLUOROPYRIDINIUM PYRIDINE HEPTAFLUORODIBORATE | ALLIED-SIGNAL INC. (US) | 1990-11-15 | — | — | WO | disclosed |
| US-4935519-A | Fluorination agent | ALLIED-SIGNAL INC. (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0204535-A1 | N-fluoropyridinium salt and process for preparing same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | TSHR 4172/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | TSHR 4172/4885 |
| US-20090149398-A1 | 6,11-3c-bicyclic 8a-azalide derivatives | CYP3A7, SBDS, UGT2B7 | TSHR 2731/4885 |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | CYP51A1, SI, VIP | TSHR 4286/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | TSHR 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.